| 0.0135 -0.007 (-33.5%) | 01-08 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.02  |
1-year : | 0.03 |
| Resists | First : | 0.01 |
Second : | 0.02 |
| Pivot price | 0.01 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 |
MA(20) : | 0.01 |
| MA(100) : | 0.02 |
MA(250) : | 0.46 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.9  |
D(3) : | 3.7 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 1.59 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ATHX ] has closed above bottom band by 13.4%. Bollinger Bands are 85.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 87 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.01 - 0.01 | 0.01 - 0.01 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Wed, 17 Apr 2024
Are Institutions Heavily Invested In Athersys, Inc.'s (NASDAQ:ATHX) Shares? - Yahoo Movies UK
Tue, 09 Jan 2024
Athersys files for bankruptcy, sells assets to Healios in wake of stroke cell therapy's struggles - Fierce Biotech
Thu, 16 Nov 2023
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights - Business Wire
Tue, 17 Oct 2023
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks - InvestorPlace
Tue, 17 Oct 2023
Athersys (NASDAQ: ATHX) stock up 40% after bankruptcy warning - yes, after - Dhaka Tribune
Tue, 10 Oct 2023
Athersys stock falls after bankruptcy warning (NASDAQ:ATHX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 6.115e+007 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 796 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.822e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -35 % |
| Return on Assets (ttm) | 908.7 % |
| Return on Equity (ttm) | -83.6 % |
| Qtrly Rev. Growth | 80000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 993200 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|